Form 8-K - Current report:
SEC Accession No. 0001437749-21-016817
Filing Date
2021-07-13
Accepted
2021-07-13 08:35:24
Documents
16
Period of Report
2021-07-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20210712_8k.htm   iXBRL 8-K 22217
2 EXHIBIT 99.1 ex_263219.htm EX-99.1 14794
7 mbrx20210712_8kimg001.jpg GRAPHIC 3787
8 moleculinlogoresizedclear.jpg GRAPHIC 19339
  Complete submission text file 0001437749-21-016817.txt   216520

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20210713.xsd EX-101.SCH 3702
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20210713_def.xml EX-101.DEF 11973
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20210713_lab.xml EX-101.LAB 16011
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20210713_pre.xml EX-101.PRE 12182
9 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20210712_8k_htm.xml XML 2683
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 211086855
SIC: 2834 Pharmaceutical Preparations